Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
Search results for: biosimilars
Advancing the Work of CORC: Q&A with New Chair Chris Phillips, MD
New Committee on Rheumatologic Care (CORC) Chair Chris Phillips, MD, talks about his past work with the ACR, his experience as a private practice rheumatologist and his plans to lead CORC in addressing practitioner pain points and supporting the business side of rheumatology practice.
Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
ACR Advocacy Staff Outline Victories, Challenges from a Busy Year
SAN DIEGO—In an advocacy update session at ACR Convergence 2023, ACR staff described progress in multiple priority areas, including access to care and workforce issues.
FDA Approves New Biosimilar for Adult & Pediatric Arthritis
This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.
‘Better Equipped to Serve the College’: A Look at CORC Achievements Through the Pandemic
Outgoing CORC Chair Marcus Snow, MD, FACR, and the College look back on the tremendous achievements made during the past three years, including pandemic care guidance, improved patient access to care and direction through new biosimilars choices.
Your Invitation Here: Learn How Advocacy Can Help You & Your Practice
Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
FDA Grants Interchangeable Designation to Pfizer’s Abrilada, Biosimilar to AbbVie’s Humira
On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Marching to the Biosimilar Beat: Questions on Rollout Remain
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
Expert Guidance from the ACR/ARP Access in Rheumatology Meeting
ACR/ARP Access in Rheumatology—As part of ACR Education Exchange 2023, the ACR/ARP Access in Rheumatology meeting addressed some of the major challenges in coverage and payment that U.S. rheumatology practices face. Speakers included rheumatologists, rheumatology professionals, office managers and CEOs. The first section, Thriving, Not Just Surviving—Keeping Your Rheumatology Practice Solvent, focused on financial management…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 32
- Next Page »